Umbilical Cord Derived Wharton's Jelly for Knee Osteoarthritis

Umbilical Cord Derived Wharton's Jelly for Treatment of Knee Osteoarthritis

The purpose of this study is to determine the safety and efficacy of intraarticular injection of umbilical cord derived Wharton's Jelly for treatment of knee osteoarthritis symptoms.

Study Overview

• Status: Not yet recruiting
• Conditions: Osteoarthritis, Knee
• Intervention / Treatment: Biological: Umbilical Cord-derived Wharton's Jelly

Detailed Description

Osteoarthritis (OA) is the most common joint disorder in the United States (US), affecting approximately 12% (~30 million) of adults aged between 25 and 74 years. By 2030, the number of US adults with arthritis is expected to reach 67 million leading to continuous increase in number of total knee replacement surgeries. While total knee replacement surgeries have shown advantages, avoiding or delaying surgery appears desirable, both from medical and health care system perspective. Lowering the number of total knee replacement surgeries will also lead to a reduced number of costly revision surgeries. Published studies have also demonstrated that the outcomes after total knee replacement surgeries for patients with Grade II or III knee OA (on Kellgren-Lawrence scale) are worse compared to patients with Grade IV OA. Conventional treatment modalities including activity modification, physical therapy, pharmacological agents such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, viscosupplementation and narcotics have limitations and potential side effects. Thus, there is a need for alternative intervention for patients with Grade II or III knee OA.

Interest in the use of biologics for regenerative medicine applications has increased over the last decade. To be compliant in the United States (U.S.), biologics that adhere to the U.S. Food and Drug Administration (FDA) regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P's) regulated under title 21, part 1271 of the Code of Federal Regulations (CFR) must meet all the conditions under section 361 of Public Health Safety (PHS) Act to be regulated solely under this section. According to this regulation, HCT/P's must meet the criteria of being minimally manipulated, for homologous use only, not to be combination products, to have no systemic effect, and to be non-dependent on the metabolic activity of the living cells. Despite increased use, there is insufficient literature assessing the amount of growth factors (GF), cytokines (CK), hyaluronic acid (HA) and extracellular vesicles (EV) including exosomes present in these products, and more specifically, umbilical cord derived Wharton's Jelly. In addition, there is limited or no literature assessing the safety and efficacy of umbilical cord derived Wharton's Jelly products via a clinical study.

To address the insufficient literature assessing the presence and quantity of GF, CK, HA and EV including exosomes, investigators formulated a novel umbilical cord derived Wharton's Jelly product and evaluated it for the presence of these factors. The results from this study demonstrated that the essential components of regenerative medicine, namely GF, CK, HA and EV, are all present in large quantities in the formulated Wharton's Jelly. This study was an essential preliminary step to better characterize this Wharton's Jelly formulation before performing clinical trials to determine safety and efficacy of this novel formulation for regenerative medicine applications.

The goal of the proposed study is to evaluate the safety and efficacy of intraarticular injection of umbilical cord derived Wharton's Jelly for treatment of knee osteoarthritis symptoms. Investigators also hypothesize that patients receiving intraarticular injection of Wharton's Jelly is safe and will show an improvement in their overall satisfaction, Numeric Pain rating Scale (NPRS), Knee Injury and Osteoarthritis Outcome Score (KOOS) and cartilage formation over a period of 1 year compared to the baseline visit.

• Study Type: Interventional
• Enrollment (Anticipated): 12
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Saadiq F. El-Amin III, MD, PhD; Phone Number: 678-257-7078; Email: dr.saadiqelamin@gmail.com
• Study Contact Backup: Name: Ashim Gupta, PhD, MBA; Email: agupta@biointegrate.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients must be 18 years or older.
2. Must have a body mass index (BMI) of < 40Kg/m2.
3. Must be able to comply with the requirements of study visits.
4. Diagnosed with mild to moderate knee osteoarthritis (OA) in one knee only - Grade 2 or 3 on the KL grading scale.
5. Pain score of 4 or more on the NPRS (on scale of 0 to 10).
6. Female patients were abstinent, surgically sterilized or postmenopausal.
7. Premenopausal females with negative pregnancy test, and who does not anticipate pregnancy and will actively practice an accepted contraceptive method for the duration of study.
8. Males with premenopausal female partners, will take contraceptive measures for the duration of study.
9. Be willing and capable of giving written informed consent to participate in this clinical study.
10. Be willing and capable of complying with study-related requirements, procedures and visits.

Exclusion Criteria:

1. Patients who have taken any pain medications including NSAIDs within 15 days (except Acetaminophen), prior to the study injection date, regularly use anticoagulants, substance abuse history, and/or failure to agree not to take any knee-symptom modifying drugs during the course of the study without discussing and reporting the use to site principal investigator and study team.
2. Patients who are positive on special tests and stability tests on the physical exam case report form.
3. Patients with intraarticular injection of any drug including corticosteroids, viscosupplementation in the index knee in last 3 months.
4. Patients with index knee surgery within last 6 months.
5. Patients with traumatic injury to index knee within last 3 months.
6. Patients with planned elective surgery during the course of the study.
7. Patients with organ or hematologic transplantation history, rheumatoid arthritis or other autoimmune disorders.
8. Patients on immunosuppressive medication/treatment, diagnosis of non-basal cell carcinoma within last 5 years.
9. Patients with knee infection or who used antibiotics for knee infection within last 3 months.
10. Patients who participated in another clinical trial or treatment with any investigational product within last 30 days prior to inclusion in the study.
11. Female patients who are breast feeding or are pregnant or desire to be pregnant during the course of the study.
12. Patients with contraindication to X-ray or MRI imaging.
13. Patients with serious neurological, psychological or psychiatric disorders.
14. Patients with other medical conditions determined by site principal investigator as interfering with the study.
15. Patients with an injury or disability claim under current litigation or pending or approved workers' compensation claim.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Wharton's Jelly; Intraarticular injection of Umbilical Cord-derived Wharton's Jelly	Biological: Umbilical Cord-derived Wharton's Jelly; Intraarticular injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-emergent adverse effects as assessed by Comprehensive Metabolic Profile	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by Comprehensive metabolic profile	1week
Treatment-emergent adverse effects as assessed by Comprehensive Metabolic Profile	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by Comprehensive metabolic profile	6weeks
Treatment-emergent adverse effects as assessed by Comprehensive Metabolic Profile	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by Comprehensive metabolic profile	3months
Treatment-emergent adverse effects as assessed by Comprehensive Metabolic Profile	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by Comprehensive metabolic profile	6months
Treatment-emergent adverse effects as assessed by Comprehensive Metabolic Profile	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by Comprehensive metabolic profile	1year
Treatment-emergent adverse effects as assessed by creatinine levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by creatinine levels	1week
Treatment-emergent adverse effects as assessed by creatinine levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by creatinine levels	6weeks
Treatment-emergent adverse effects as assessed by creatinine levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by creatinine levels	3months
Treatment-emergent adverse effects as assessed by creatinine levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by creatinine levels	6months
Treatment-emergent adverse effects as assessed by creatinine levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by creatinine levels	1year
Treatment-emergent adverse effects as assessed by liver function tests	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by liver function tests	1week
Treatment-emergent adverse effects as assessed by liver function tests	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by liver function tests	6weeks
Treatment-emergent adverse effects as assessed by liver function tests	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by liver function tests	3months
Treatment-emergent adverse effects as assessed by liver function tests	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by liver function tests	6months
Treatment-emergent adverse effects as assessed by liver function tests	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by liver function tests	1year
Treatment-emergent adverse effects as assessed by complete blood count	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by complete blood count	1week
Treatment-emergent adverse effects as assessed by complete blood count	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by complete blood count	6weeks
Treatment-emergent adverse effects as assessed by complete blood count	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by complete blood count	3months
Treatment-emergent adverse effects as assessed by complete blood count	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by complete blood count	6months
Treatment-emergent adverse effects as assessed by complete blood count	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by complete blood count	1year
Treatment-emergent adverse effects as assessed by C-reactive protein	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by C-reactive protein	1week
Treatment-emergent adverse effects as assessed by C-reactive protein	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by C-reactive protein	6weeks
Treatment-emergent adverse effects as assessed by C-reactive protein	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by C-reactive protein	3months
Treatment-emergent adverse effects as assessed by C-reactive protein	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by C-reactive protein	6months
Treatment-emergent adverse effects as assessed by C-reactive protein	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by C-reactive protein	1year
Treatment-emergent adverse effects as assessed by erythrocyte sedimentation rate	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by erythrocyte sedimentation rate	1week
Treatment-emergent adverse effects as assessed by erythrocyte sedimentation rate	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by erythrocyte sedimentation rate	6weeks
Treatment-emergent adverse effects as assessed by erythrocyte sedimentation rate	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by erythrocyte sedimentation rate	3months
Treatment-emergent adverse effects as assessed by erythrocyte sedimentation rate	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by erythrocyte sedimentation rate	6months
Treatment-emergent adverse effects as assessed by erythrocyte sedimentation rate	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by erythrocyte sedimentation rate	1year
Treatment-emergent adverse effects as assessed by T, B and NK cell lymphocyte subsets	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by T, B and NK cell lymphocyte subsets	1week
Treatment-emergent adverse effects as assessed by T, B and NK cell lymphocyte subsets	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by T, B and NK cell lymphocyte subsets	6weeks
Treatment-emergent adverse effects as assessed by T, B and NK cell lymphocyte subsets	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by T, B and NK cell lymphocyte subsets	3months
Treatment-emergent adverse effects as assessed by T, B and NK cell lymphocyte subsets	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by T, B and NK cell lymphocyte subsets	6months
Treatment-emergent adverse effects as assessed by T, B and NK cell lymphocyte subsets	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by T, B and NK cell lymphocyte subsets	1year
Treatment-emergent adverse effects as assessed by serum IgG, IgA, IgM and IgE levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by serum IgG, IgA, IgM and IgE levels	1week
Treatment-emergent adverse effects as assessed by serum IgG, IgA, IgM and IgE levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by serum IgG, IgA, IgM and IgE levels	6weeks
Treatment-emergent adverse effects as assessed by serum IgG, IgA, IgM and IgE levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by serum IgG, IgA, IgM and IgE levels	3months
Treatment-emergent adverse effects as assessed by serum IgG, IgA, IgM and IgE levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by serum IgG, IgA, IgM and IgE levels	6months
Treatment-emergent adverse effects as assessed by serum IgG, IgA, IgM and IgE levels	To determine safety i.e. adverse events associated with intraarticular administration of Umbilical cord-derived Wharton's Jelly as assessed by serum IgG, IgA, IgM and IgE levels	1year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 24hours after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 48hours after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 1week after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 6weeks after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 1year after injection
Change in patient reported outcome measures, Knee Injury and Osteoarthritis Outcome Score	To determine change in patient reported outcome measure, Knee Injury and Osteoarthritis Outcome Score (KOOS). An increase in score indicates improvement.	Change from baseline to 1week after injection
Change in patient reported outcome measures, Knee Injury and Osteoarthritis Outcome Score	To determine change in patient reported outcome measure, Knee Injury and Osteoarthritis Outcome Score (KOOS). An increase in score indicates improvement.	Change from baseline to 6weeks after injection
Cartilage Formation	To assess cartilage formation via MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue). An increase in score indicates improvement.	Change from baseline to 1year after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to immediately after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 3months after injection
Change in patient reported outcome measures, Numeric Pain Rating Scale	To determine change in patient reported outcome measure, Numeric Pain Rating Scale (NPRS). A decrease in score indicates improvement.	Change from baseline to 6months after injection
Change in patient reported outcome measures, Knee Injury and Osteoarthritis Outcome Score	To determine change in patient reported outcome measure, Knee Injury and Osteoarthritis Outcome Score (KOOS). An increase in score indicates improvement.	Change from baseline to 3months after injection
Change in patient reported outcome measures, Knee Injury and Osteoarthritis Outcome Score	To determine change in patient reported outcome measure, Knee Injury and Osteoarthritis Outcome Score (KOOS). An increase in score indicates improvement.	Change from baseline to 6months after injection
Change in patient reported outcome measures, Knee Injury and Osteoarthritis Outcome Score	To determine change in patient reported outcome measure, Knee Injury and Osteoarthritis Outcome Score (KOOS). An increase in score indicates improvement.	Change from baseline to 1year after injection
Patient Satisfaction via 36-item short form survey (SF36)	To determine patient satisfaction via 36-item short form survey (SF36)	Change from baseline to 3Months after injection
Patient Satisfaction via 36-item short form survey (SF36)	To determine patient satisfaction via 36-item short form survey (SF36)	Change from baseline to 6Months after injection
Patient Satisfaction via 36-item short form survey (SF36)	To determine patient satisfaction via 36-item short form survey (SF36)	Change from baseline to 1year after injection
Patient Satisfaction via 7-point Likert Scale	To determine patient satisfaction via 7-point Likert Scale. An increase in score indicates improvement.	1week after injection
Patient Satisfaction via 7-point Likert Scale	To determine patient satisfaction via 7-point Likert Scale. An increase in score indicates improvement.	6weeks after injection
Patient Satisfaction via 7-point Likert Scale	To determine patient satisfaction via 7-point Likert Scale. An increase in score indicates improvement.	3months after injection
Patient Satisfaction via 7-point Likert Scale	To determine patient satisfaction via 7-point Likert Scale. An increase in score indicates improvement.	6months after injection
Patient Satisfaction via 7-point Likert Scale	To determine patient satisfaction via 7-point Likert Scale. An increase in score indicates improvement.	1year after injection
Patient Satisfaction via Single Assessment Numeric Evaluation (SANE)	To determine patient satisfaction via Single Assessment Numeric Evaluation (SANE). An increase in score indicates improvement.	Change from baseline to 1week after injection
Patient Satisfaction via Single Assessment Numeric Evaluation (SANE)	To determine patient satisfaction via Single Assessment Numeric Evaluation (SANE). An increase in score indicates improvement.	Change from baseline to 6weeks after injection
Patient Satisfaction via Single Assessment Numeric Evaluation (SANE)	To determine patient satisfaction via Single Assessment Numeric Evaluation (SANE). An increase in score indicates improvement.	Change from baseline to 3months after injection
Patient Satisfaction via Single Assessment Numeric Evaluation (SANE)	To determine patient satisfaction via Single Assessment Numeric Evaluation (SANE). An increase in score indicates improvement.	Change from baseline to 6months after injection
Patient Satisfaction via Single Assessment Numeric Evaluation (SANE)	To determine patient satisfaction via Single Assessment Numeric Evaluation (SANE). An increase in score indicates improvement.	Change from baseline to 1year after injection

Collaborators and Investigators

• Sponsor: BioIntegrate
• Investigators: Principal Investigator: Saadiq F. El-Amin III, MD, PhD, El-Amin Orthopaedic & Sports Medicine Institute; Study Director: Ashim Gupta, PhD, MBA, BioIntegrate

Publications and helpful links

General Publications

• Gupta A, Maffulli N, Rodriguez HC, Lee CE, Levy HJ, El-Amin SF 3rd. Umbilical cord-derived Wharton's jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial. J Orthop Surg Res. 2021 Feb 18;16(1):143. doi: 10.1186/s13018-021-02300-0.

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2023
• Primary Completion (Anticipated): December 31, 2024
• Study Completion (Anticipated): December 31, 2024

Study Registration Dates

• First Submitted: January 14, 2021
• First Submitted That Met QC Criteria: January 18, 2021
• First Posted (Actual): January 22, 2021

Study Record Updates

• Last Update Posted (Actual): July 21, 2022
• Last Update Submitted That Met QC Criteria: July 20, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: Knee Osteoarthritis; Umbilical Cord; Wharton's Jelly
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Knee
• Other Study ID Numbers: BIOINT - 2020UCWJ/knee OA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No